Pediatric Glomerular Disease
By:
Eugene Yu-hin Chan Paediatric Nephrology Centre, Hong Kong Children’s Hospital, Hong Kong Department of Paediatrics, Chinese University of Hong Kong, Shatin, Hong Kong SAR

Search for other papers by Eugene Yu-hin Chan in
Current site
Google Scholar
PubMed Close
,
Olivia Boyer Néphrologie Pédiatrique, Centre de Référence du syndrome néphrotique idiopathique de l’enfant et l’adulte, Hôpital Necker - Enfants Malades, Assistance Publique – Hôpitaux de Paris, Inserm U1163, Institut Imagine, Université Paris Cité, Paris, France

Search for other papers by Olivia Boyer in
Current site
Google Scholar
PubMed Close
, and
Kjell Tullus Department of Paediatric Nephrology, Great Ormond Street Hospital for Children, London, United Kingdom

Search for other papers by Kjell Tullus in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 23: Issue 1
Published Online:
May 2024
Restricted access
Purchase Print On-Demand ASN Members Sign In Here
  • Collapse
  • Expand
Cover Nephrology Self-Assessment Program
Copyright:
Copyright © 2024 by the American Society of Nephrology 2024
Page Count:
11
Article Category:
Research Article
Print Publication Date:
01 May 2024
Published Online:
May 2024
  • 1.

    Ingelfinger JR, Schaefer F, Kalantar-Zadeh K: Averting the legacy of kidney disease-focus on childhood. Kidney Int 89: 512–518, 2016 PubMed

  • 2.

    O’Shaughnessy MM, Hogan SL, Poulton CJ, Falk RJ, Singh HK, Nickeleit V, et al.: Temporal and demographic trends in glomerular disease epidemiology in the southeastern United States, 1986–2015. Clin J Am Soc Nephrol 12: 614–623, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    O’Shaughnessy MM, Hogan SL, Thompson BD, Coppo R, Fogo AB, Jennette JC: Glomerular disease frequencies by race, sex and region: Results from the International Kidney Biopsy Survey. Nephrol Dial Transplant 33: 661–669, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, et al.: Complete remission in the nephrotic syndrome study network. Clin J Am Soc Nephrol 11: 81–89, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, et al.: IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 35: 1529–1561, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Mason AE, Sen ES, Bierzynska A, Colby E, Afzal M, Dorval G, et al.: Response to first course of intensified immunosuppression in genetically stratified steroid resistant nephrotic syndrome. Clin J Am Soc Nephrol 15: 983–994, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Tullus K: Why FSGS keeps being presented as a disease although it is not. Nephrol Dial Transplant 38: 2426–2427, 2023 PubMed

  • 8.

    Veltkamp F, Rensma LR, Bouts AH: Incidence and relapse of idiopathic nephrotic syndrome: meta-analysis. Pediatrics 148: e2020029249, 2021 PubMed

  • 9.

    Veltkamp F, Thenot V, Mussies C, van Lieshout B, Peters-Sengers H, Kers J, et al.: Incidence of idiopathic nephrotic syndrome during the Covid-19 pandemic in the Paris area (France) and in the Netherlands. Pediatr Nephrol 38: 3681–3692, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Watts AJ, Keller KH, Lerner G, Rosales I, Collins AB, Sekulic M, et al.: Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J Am Soc Nephrol 33: 238–252, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Vivarelli M, Gibson K, Sinha A, Boyer O: Childhood nephrotic syndrome. Lancet 402: 809–824, 2023 PubMed

  • 12.

    Barry A, McNulty MT, Jia X, Gupta Y, Debiec H, Luo Y, et al.: Multi-population genome-wide association study implicates immune and non-immune factors in pediatric steroid-sensitive nephrotic syndrome. Nat Commun 14: 2481, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Dorval G, Servais A, Boyer O: The genetics of steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 37: 648–651, 2022 PubMed

  • 14.

    Dorval G, Kuzmuk V, Gribouval O, Welsh GI, Bierzynska A, Schmitt A, et al.: TBC1D8B loss-of-function mutations lead to X-linked nephrotic syndrome via defective trafficking pathways. Am J Hum Genet 104: 348–355, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al.: Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 100: 753–779, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S, et al.: IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38: 877–919, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Gargiulo A, Massella L, Ruggiero B, Ravà L, Degli Atti MC, Materassi M, et al.: Results of the PROPINE randomized controlled study suggest tapering of prednisone treatment for relapses of steroid sensitive nephrotic syndrome is not necessary in children. Kidney Int 99: 475–483, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Kainth D, Hari P, Sinha A, Pandey S, Bagga A: Short-duration prednisolone in children with nephrotic syndrome relapse: A noninferiority randomized controlled trial. Clin J Am Soc Nephrol 16: 225–232, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Christian MT, Webb NJ, Mehta S, Woolley RL, Afentou N, Frew E, et al.: Evaluation of daily low-dose prednisolone during upper respiratory tract infection to prevent relapse in children with relapsing steroid-sensitive nephrotic syndrome: The PREDNOS 2 randomized clinical trial. JAMA Pediatr 176: 236–243, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Sinha A, Devi KG, Kalra S, Kalaivani M, Hari P, Bagga A: An open label non-inferiority RCT evaluated alternate day prednisolone given daily during infections vs. levamisole in frequently relapsing nephrotic syndrome. Kidney Int 105: 1113–1123, 2024

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T, et al.: Mycophenolate mofetil after rituximab for childhood-onset complicated frequently-relapsing or steroid-dependent nephrotic syndrome. J Am Soc Nephrol 33: 401–419, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Chan EY, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL, et al.: Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int 97: 393–401, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Sinha A, Mathew G, Arushi A, Govindarajan S, Ghanapriya K, Grewal N, et al.: Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects. Nephrol Dial Transplant 38: 939–949, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Chan EY, Ellen L, Angeletti A, Arslan Z, Basu B, Boyer O, et al.: Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study. J Am Soc Nephrol 33: 1193–1207, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Chan EY, Tullus K: Rituximab in children with steroid sensitive nephrotic syndrome: in quest of the optimal regimen. Pediatr Nephrol 36: 1397–1405, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Chan EY, Ma AL, Tullus K: Hypogammaglobulinaemia following rituximab therapy in childhood nephrotic syndrome. Pediatr Nephrol 37: 927–931, 2022 PubMed

  • 27.

    Trautmann A, Seide S, Lipska-Ziętkiewicz BS, Ozaltin F, Szczepanska M, Azocar M, et al.: Outcomes of steroid-resistant nephrotic syndrome in children not treated with intensified immunosuppression. Pediatr Nephrol 38: 1499–1511, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Malakasioti G, Iancu D, Milovanova A, Tsygin A, Horinouchi T, Nozu K, et al.: A multicenter retrospective study of calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene variants. Kidney Int 103: 962–972, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Drovandi S, Lipska-Ziętkiewicz BS, Ozaltin F, Emma F, Gulhan B, Boyer O, et al.: Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiency. Kidney Int 102: 604–612, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Egbuna O, Zimmerman B, Manos G, Fortier A, Chirieac MC, Dakin LA, et al.: Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants. N Engl J Med 388: 969–979, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Morello W, Proverbio E, Puccio G, Montini G: A systematic review and meta-analysis of the rate and risk factors for post-transplant disease recurrence in children with steroid resistant nephrotic syndrome. Kidney Int Rep 8: 254–264, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Ding WY, Koziell A, McCarthy HJ, Bierzynska A, Bhagavatula MK, Dudley JA, et al.: Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence. J Am Soc Nephrol 25: 1342–1348, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Chan EY, Lai FF, Ma AL, Chan TM: Managing lupus nephritis in children and adolescents., Pediatr Drugs 26: 145–161, 2023 PubMed

  • 34.

    Wenderfer SE, Chang JC, Davies AG, Luna IY, Scobell R, Sears C, et al.: Using a multi-institutional pediatric learning health system to identify systemic lupus erythematosus and lupus nephritis: Development and validation of computable phenotypes. Clin J Am Soc Nephrol 17: 65–74, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Chan EY, Yap DY, Wong W, Wong WH, Wong S, Lin KY, et al.: Long-term outcomes of children and adolescents with biopsy-proven childhood-onset lupus nephritis. Kidney Int Rep 8: 141–150, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Chan EY, Yap DY, Wong WH, Wong S, Lin KY, Hui FY, et al.: Renal relapse in children and adolescents with childhood-onset lupus nephritis: a 20-year study. Rheumatology (Oxford) 63: 953–961, 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Groot N, De Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B, et al.: European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis 76: 1965–1973, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al.: KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100: S1–S276, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    De Mutiis C, Wenderfer SE, Orjuela A, Bagga A, Basu B, Sar T, et al.: Defining renal remission in an international cohort of 248 children and adolescents with lupus nephritis. Rheumatology (Oxford) 61: 2563–2571, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Aragon E, Resontoc L, Chan Y, Lau Y, Tan P, Loh H, et al.: Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis. Lupus 25: 399–406, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Smith EMD, Aggarwal A, Ainsworth J, Al-Abadi E, Avcin T, Bortey L, et al.: Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force. Ann Rheum Dis 82: 788–798, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Tselios K, Gladman DD, Urowitz MB: How can we define low disease activity in systemic lupus erythematosus? Semin Arthrit Rheum 48: 1035–1040, 2019 PubMed

  • 43.

    Kisaoglu H, Baba O, Kalyoncu M: Lupus low disease activity state as a treatment target for pediatric patients with lupus nephritis. Pediatr Nephrol 38: 1167–1175, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Wahadat MJ, Van Den Berg L, Timmermans D, Van Rijswijk K, van Dijk-Hummelman A, Bakx S, et al.: LLDAS is an attainable treat-to-target goal in childhood-onset SLE. Lupus Sci Med 8: e000571, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y, et al.: Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 27: 1467–1472, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Rathi M, Goyal A, Jaryal A, Sharma A, Gupta PK, Ramachandran R, et al.: Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int 89: 235–242, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al.: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20: 1103–1112, 2009 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Cannon LA, Wenderfer SE, Lewandowski LB, Cooper JC, Goilav B, Knight AM, et al.: Use of EuroLupus cyclophosphamide dosing for the treatment of lupus nephritis in childhood-onset systemic lupus erythematosus in North America. J Rheumatol 49: 607–614, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Wang CS, Sadun RE, Zhou W, Miller KR, Pyle L, Ardoin SP, et al.: Renal response outcomes of the EuroLupus and NIH cyclophosphamide dosing regimens in childhood‐onset proliferative lupus nephritis. Arthritis Rheumatol 76: 469–478, 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Smitherman EA, Chahine RA, Beukelman T, Lewandowski LB, Rahman AF, Wenderfer SE, et al.: Childhood‐onset lupus nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short‐term kidney status and variation in care. Arthritis Care Res (Hoboken) 75: 1553–1562, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Chalhoub NE, Wenderfer SE, Levy DM, Rouster‐Stevens K, Aggarwal A, Savani SI, et al.: International consensus for the dosing of corticosteroids in childhood‐onset systemic lupus erythematosus with proliferative lupus nephritis. Arthritis Rheumatol 74: 263–273, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Basu B, Roy B, Babu BG: Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol 32: 1013–1021, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Hogan J, Godron A, Baudouin V, Kwon T, Harambat J, Deschênes G, et al.: Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis. Pediatr Nephrol 33: 111–116, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G: Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol 23: 413–419, 2008 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Chan EY-h, Wong S-w, Lai FF-y, Ho T-w, Tong P-c, Lai W-m, et al.: Long-term outcomes with rituximab as add-on therapy in severe childhood-onset lupus nephritis. Pediatr Nephrol 38: 4001–4011, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Furie R, Rovin BH, Houssiau F, Malvar A, Teng YO, Contreras G, et al.: Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383: 1117–1128, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Rovin BH, Teng YO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, et al.: Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397: 2070–2080, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al.: B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81: 100–107, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Marlais M, Wlodkowski T, Printza N, Kronsteiner D, Krisam R, Sauer L, et al.: Clinical factors and adverse kidney outcomes in children with antineutrophil cytoplasmic antibody–associated glomerulonephritis. Am J Kidney Dis 81: 119–122, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Cabral DA, Canter DL, Muscal E, Nanda K, Wahezi DM, Spalding SJ, et al.: Comparing presenting clinical features in 48 children with microscopic polyangiitis to 183 children who have granulomatosis with polyangiitis (Wegener’s): An ARChiVe cohort study. Arthritis Rheumatol 68: 2514–2526, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Calatroni M, Consonni F, Allinovi M, Bettiol A, Jawa N, Fiasella S, et al.: Prognostic factors and long-term outcome with ANCA-associated kidney vasculitis in childhood. Clin J Am Soc Nephrol 16: 1043–1051, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Maliakkal JG, Hicks MJ, Michael M, Selewski DT, Twombley K, Rheault MN, et al.: Renal survival in children with glomerulonephritis with crescents: A Pediatric Nephrology Research Consortium cohort study. J Clin Med 9: 2385, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Chen A, Mammen C, Guzman J, Al-Abadi E, Benseler SM, Berard RA, et al.: Wide variation in glucocorticoid dosing in paediatric ANCA-associated vasculitis with renal disease: A paediatric vasculitis initiative study. Clin Exp Rheumatol 40: 841–848, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, et al.: Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: A randomized clinical trial. JAMA 325: 2178–2187, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Walsh M, Merkel PA, Peh C-A, Szpirt WM, Puéchal X, Fujimoto S, et al.: Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 382: 622–631, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Walsh M, Collister D, Zeng L, Merkel PA, Pusey CD, Guyatt G, et al.: The effects of plasma exchange in patients with ANCA-associated vasculitis: An updated systematic review and meta-analysis. BMJ 376: e064604, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Jayne DR, Merkel PA, Schall TJ, Bekker P: Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384: 599–609, 2021 PubMed

  • 68.

    Pohl M: Henoch-Schonlein purpura nephritis. Pediatr Nephrol 30: 245–252, 2015 PubMed

  • 69.

    Davin JC, Coppo R: Pitfalls in recommending evidence-based guidelines for a protean disease like Henoch-Schonlein purpura nephritis. Pediatr Nephrol 28: 1897–1903, 2013 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Willey CJ, Coppo R, Schaefer F, Mizerska-Wasiak M, Mathur M, Schultz MJ: The incidence and prevalence of IgA nephropathy in Europe. Nephrol Dial Transplant 38: 2340–2349, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    El Karoui K, Fervenza FC, De Vriese AS: Treatment of IgA nephropathy: A rapidly evolving field. J Am Soc Nephrol 35: 103–116, 2024 PubMed

  • 72.

    Cattran DC, Floege J, Coppo R: Evaluating progression risk in patients with Immunoglobulin A nephropathy. Kidney Int Rep 8: 2515–2528, 2023 PubMed

  • 73.

    Howie AJ, Lalayiannis AD: Systematic review of the Oxford classification of IgA nephropathy: Reproducibility and prognostic value. Kidney360 4: 1103–1111, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Barbour SJ, Coppo R, Er L, Russo ML, Liu ZH, Ding J, et al.: Updating the International IgA Nephropathy Prediction Tool for use in children. Kidney Int 99: 1439–1450, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Ying D, Lu M, Zhi Y, Shi P, Cao L, Wang Q, et al.: External validation of the pediatric International IgA Nephropathy Prediction Tool in a central China cohort. Clin Exp Nephrol 28: 59–66, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Yu X, Li J, Tao C, Jiao J, Wan J, Zhong C, et al.: Validation of the children international IgA nephropathy prediction tool based on data in Southwest China. Front Pediatr 11: 1183562, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Thompson A, Carroll K, Inker LA, Floege J, Perkovic V, Boyer-Suavet S, et al.: Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 14: 469–481, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Inker LA, Heerspink HJL, Tighiouart H, Chaudhari J, Miao S, Diva U, et al.: Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: An individual participant meta-analysis. Am J Kidney Dis 78: 340–349.e1, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Inker LA, Lambers Heerspink HJ, Mondal H, Schmid CH, Tighiouart H, Noubary F, et al.: GFR decline as an alternative end point to kidney failure in clinical trials: A meta-analysis of treatment effects from 37 randomized trials. Am J Kidney Dis 64: 848–859, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Chan EY-h, Ma AL-t, Tullus K: When should we start and stop ACEi/ARB in paediatric chronic kidney disease? Pediatr Nephrol 36: 1751–1764, 2021 PubMed

  • 81.

    Floege J, Rauen T, Eitner F: Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 374: 992–993, 2016 PubMed

  • 82.

    Dixon A, Blanchette E, Kendrick J: A lack of KDIGO guidelines for adolescents and young adults with IgA nephropathy. Pediatr Nephrol 39: 297–304, 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Coppo R: Treatment of IgA nephropathy in children: A land without KDIGO guidance. Pediatr Nephrol 36: 491–496, 2021 PubMed

  • 84.

    Vaz de Castro PAS, Bitencourt L, Pereira BWS, Lima AQR, Hermida HS, Moreira Neto CR, et al.: Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children. Pediatr Nephrol 37: 499–508, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, et al.: Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 318: 432–442, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, et al.: Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 327: 1888–1898, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Zhao H, Li Y, Sun J, Xu G, Wang C, Zhou S, et al.: Immunosuppression versus supportive care on kidney outcomes in IgA nephropathy in the real-world setting. Clin J Am Soc Nephrol 18: 1186–1194, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Zhang YM, Lv JC, Wong MG, Zhang H, Perkovic V: Glucocorticoids for IgA nephropathy-pro. Kidney Int 103: 666–669, 2023 PubMed

  • 89.

    Cheung CK, Barratt J: First do no harm: Systemic glucocorticoids should not be used for the treatment of progressive IgA nephropathy. Kidney Int 103: 669–673, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, et al.: Sparsentan in patients with IgA nephropathy: A prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 401: 1584–1594, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, et al.: Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet 402: 2077–2090, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Reich HN, Barbour SJ: PROTECTing the kidneys in IgA nephropathy. Lancet 402: 2046–2047, 2023 PubMed

  • 93.

    Wheeler DC, Toto RD, Stefansson BV, Jongs N, Chertow GM, Greene T, et al.: A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 100: 215–224, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, et al.: Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int 103: 391–402, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Lafayette R, Kristensen J, Stone A, Floege J, Tesar V, Trimarchi H, et al.: Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet 402: 859–870, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    Antonucci L, Colucci M, Emma F, Vivarelli M: A pediatric case of IgA nephropathy benefitting from targeted release formulation-budesonide. Pediatr Nephrol 38: 3849–3852, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Zhang H, Rizk DV, Perkovic V, Maes B, Kashihara N, Rovin B, et al.: Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int 105: 189–199, 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Peruzzi L, Coppo R: IgA vasculitis nephritis in children and adults: One or different entities? Pediatr Nephrol 36: 2615–2625, 2021 PubMed

  • 99.

    Terano C, Hamada R, Tatsuno I, Hamasaki Y, Araki Y, Gotoh Y, et al.: Epidemiology of biopsy-proven Henoch-Schonlein purpura nephritis in children: A nationwide survey in Japan. PLoS One 17: e0270796, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Selewski DT, Ambruzs JM, Appel GB, Bomback AS, Matar RB, Cai Y, et al.: Clinical characteristics and treatment patterns of children and adults with IgA nephropathy or IgA vasculitis: Findings from the CureGN study. Kidney Int Rep 3: 1373–1384, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Hastings MC, Rizk DV, Kiryluk K, Nelson R, Zahr RS, Novak J, et al.: IgA vasculitis with nephritis: Update of pathogenesis with clinical implications. Pediatr Nephrol 37: 719–733, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102.

    Kurokawa M, Maehara K, Kaku Y, Honjo S: Necessity and choice of therapy for Henoch-Schonlein purpura nephritis. Pediatr Int (Roma) 64: e15282, 2022 PubMed

  • 103.

    Deki S, Hamada R, Mikami N, Terano C, Harada R, Hamasaki Y, et al.: Half of children with IgA vasculitis-associated nephritis with nephrotic state spontaneously recover. Nephrology (Carlton) 27: 681–689, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Rohner K, Marlais M, Ahn YH, Ali A, Alsharief A, Novak AB, et al.: Outcome of immunosuppression in children with IgA vasculitis-related nephritis [published online ahead of print Jan 11, 2024]. Nephrol Dial Transplant doi:10.1093/ndt/gfae0092024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Ozen S, Marks SD, Brogan P, Groot N, de Graeff N, Avcin T, et al.: European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis—The SHARE initiative. Rheumatology (Oxford) 58: 1607–1616, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Stone HK, Mitsnefes M, Dickinson K, Burrows EK, Razzaghi H, Luna IY, et al.: Clinical course and management of children with IgA vasculitis with nephritis. Pediatr Nephrol 38: 3721–3733, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    Nagai S, Horinouchi T, Ninchoji T, Kondo A, Aoto Y, Ishiko S, et al.: Use of renin-angiotensin system inhibitors as initial therapy in children with Henoch-Schonlein purpura nephritis of moderate severity. Pediatr Nephrol 37: 1845–1853, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 108.

    Mary AL, Clave S, Rousset-Rouviere C, Berard E, Boyer O, Decramer S, et al.: Outcome of children with IgA vasculitis with nephritis treated with steroids: A matched controlled study. Pediatr Nephrol 38: 3317–3326, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Lee MH, Chan EY, Ma AL: Timely and individualized use of immunosuppression is associated with favourable outcomes in paediatric IgA Vasculitis Nephritis. Pediatr Nephrol 37: 913–914, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 6638 6638 4979
Full Text Views 108 108 16
PDF Downloads 153 153 21